Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Medacta Group SA ( (CH:MOVE) ) has issued an announcement.
Medacta Group SA reported a strong financial performance for 2024, with revenue increasing by 16.2% in constant currency to Euro 590.6 million and an adjusted EBITDA margin of 28.0%. The company attributes its success to innovative product launches, such as the GMK SpheriKA knee implant and the NextAR Rod Optimizer, which enhance surgical planning and patient outcomes. Medacta’s expansion efforts, including facility enlargements and workforce growth, aim to meet rising demand and support future growth. The company anticipates continued revenue growth in 2025, driven by its commitment to cutting-edge technologies and personalized medical solutions.
More about Medacta Group SA
Medacta Group SA operates in the medical technology industry, focusing on innovative orthopedic solutions. The company specializes in minimally invasive techniques and personalized solutions for joint replacement surgeries, including hip, knee, shoulder, and spine, with a strong emphasis on surgeon education and patient satisfaction.
YTD Price Performance: 22.64%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.87B
For detailed information about MOVE stock, go to TipRanks’ Stock Analysis page.